PMID- 11565834
OWN - NLM
STAT- MEDLINE
DCOM- 20020308
LR  - 20201215
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 24
IP  - 4
DP  - 2001 Jul-Aug
TI  - Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a 
      wide variety of tumor types.
PG  - 323-33
AB  - An autologous melanoma cell line selected for loss of expression of the 
      immunodominant MART-1 and gp100 antigens was initially used to carry out a mixed 
      lymphocyte tumor culture (MLTC) in a patient who expressed the human leukocyte 
      antigen (HLA)-AI and HLA-A2 class I major histocompatibility complex alleles. Ten 
      clones identified from this MLTC seemed to recognize melanoma in an 
      HLA-A1-restricted manner but failed to recognize a panel of previously described 
      melanoma antigens. The screening of an autologous melanoma cDNA library with one 
      HLA-Al-restricted melanoma-reactive T-cell clone resulted in the isolation of a 
      cDNA clone called AIM-2 (antigen isolated from immunoselected melanoma-2). The 
      AIM-2 transcript seemed to have retained an intronic sequence based on its 
      alignment with genomic sequences as well as expressed sequence tags. This 
      transcript was not readily detected after Northern blot analysis of melanoma 
      mRNA, indicating that only low levels of this product may be expressed in tumor 
      cells. Quantitative reverse transcriptase-polymerase chain reaction analysis, 
      however, demonstrated a correlation between T-cell recognition and expression in 
      HLA-A1-expressing tumor cell lines. A peptide that was encoded within a short 
      open reading frame of 23 amino acids and conformed to the HLA-A1 binding motif 
      RSDSGQQARY was found to represent the T-cell epitope. The AIM-2-reactive T-cell 
      clone recognized a number of neuroectodermal tumors as well as breast, ovarian, 
      and colon carcinomas that expressed HLA-A1, indicating that this represents a 
      widely expressed tumor antigen. Thus, AIM-2 may represent a potential target for 
      the development of vaccines in patients bearing tumors of a variety of 
      histologies.
FAU - Harada, M
AU  - Harada M
AD  - Kurume University School of Medicine, Fukuoka, Japan.
FAU - Li, Y F
AU  - Li YF
FAU - El-Gamil, M
AU  - El-Gamil M
FAU - Ohnmacht, G A
AU  - Ohnmacht GA
FAU - Rosenberg, S A
AU  - Rosenberg SA
FAU - Robbins, P F
AU  - Robbins PF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (AIM2 protein, human)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A1 Antigen)
RN  - 0 (Nuclear Proteins)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antigens, Neoplasm/*immunology
MH  - Base Sequence
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cells, Cultured
MH  - DNA-Binding Proteins
MH  - Epitopes/immunology
MH  - Gene Expression
MH  - HLA-A1 Antigen/*immunology
MH  - Humans
MH  - Interferon-gamma/*isolation & purification
MH  - Lymphocyte Culture Test, Mixed
MH  - Melanoma/*immunology
MH  - Molecular Sequence Data
MH  - Nuclear Proteins/*genetics/*isolation & purification
MH  - Tumor Cells, Cultured
EDAT- 2001/09/22 10:00
MHDA- 2002/03/09 10:01
CRDT- 2001/09/22 10:00
PHST- 2001/09/22 10:00 [pubmed]
PHST- 2002/03/09 10:01 [medline]
PHST- 2001/09/22 10:00 [entrez]
AID - 10.1097/00002371-200107000-00008 [doi]
PST - ppublish
SO  - J Immunother. 2001 Jul-Aug;24(4):323-33. doi: 10.1097/00002371-200107000-00008.